Hugel Inc
KOSDAQ:145020
Intrinsic Value
Hugel, Inc. engages in the manufacture and sale of biopharmaceuticals based on clostridium botulinum. [ Read More ]
The intrinsic value of one Hugel Inc stock under the Base Case scenario is 203 579.1 KRW. Compared to the current market price of 210 000 KRW, Hugel Inc is Overvalued by 3%.
Valuation Backtest
Hugel Inc
Run backtest to discover the historical profit from buying and selling Hugel Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Hugel Inc
Current Assets | 567.8B |
Cash & Short-Term Investments | 479.2B |
Receivables | 49.1B |
Other Current Assets | 39.5B |
Non-Current Assets | 361.5B |
Long-Term Investments | 21B |
PP&E | 134.7B |
Intangibles | 182.3B |
Other Non-Current Assets | 23.4B |
Current Liabilities | 57.4B |
Accounts Payable | 2.9B |
Accrued Liabilities | 4.6B |
Other Current Liabilities | 49.8B |
Non-Current Liabilities | 124.5B |
Long-Term Debt | 89.9B |
Other Non-Current Liabilities | 34.6B |
Earnings Waterfall
Hugel Inc
Revenue
|
319.7B
KRW
|
Cost of Revenue
|
-73.5B
KRW
|
Gross Profit
|
246.2B
KRW
|
Operating Expenses
|
-128.4B
KRW
|
Operating Income
|
117.8B
KRW
|
Other Expenses
|
-24.7B
KRW
|
Net Income
|
93.1B
KRW
|
Free Cash Flow Analysis
Hugel Inc
Profitability Score
Profitability Due Diligence
Hugel Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Hugel Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Hugel Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Hugel Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Hugel Inc
According to Wall Street analysts, the average 1-year price target for Hugel Inc is 225 547.5 KRW with a low forecast of 181 800 KRW and a high forecast of 262 500 KRW.
Shareholder Return
Price
Hugel Inc
Average Annual Return | 1.86% |
Standard Deviation of Annual Returns | 30.24% |
Max Drawdown | -62% |
Market Capitalization | 2.3T KRW |
Shares Outstanding | 11 258 200 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Hugel, Inc. engages in the manufacture and sale of biopharmaceuticals based on clostridium botulinum. The company is headquartered in Chuncheon, Gangwon-Do. The company went IPO on 2015-12-24. The firm's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The firm sells its products in domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Hugel Inc stock under the Base Case scenario is 203 579.1 KRW.
Compared to the current market price of 210 000 KRW, Hugel Inc is Overvalued by 3%.